dihydrometanicotine | 3000-74-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: dihydrometanicotine
• 英文别名: methyl-(4-pyridin-3-yl-butyl)-amine；methyl-(4-[3]pyridyl-butyl)-amine；Methyl-(4-[3]pyridyl-butyl)-amin；4-(3-pyridyl)-N-methyl-butylamine；N-methyl-4-(pyridin-3-yl)butylamine；N-Methyl-3-pyridinebutanamine Dihydrochloride；N-methyl-4-pyridin-3-ylbutan-1-amine
• CAS: 3000-74-6
• 化学式: C₁₀H₁₆N₂
• 分子量: 164.25
• InChiKey: UZEWTSSWPCYGLO-UHFFFAOYSA-N

物化性质

• 溶解度：
  甲醇（微溶）、水（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  dihydrometanicotine 、 3-cyano-6-ethoxycarbonyl-4-(2-fluorobenzyl)-2-(4-methoxyphenyl)-1-methylpyrrolo[1,2-a]pyrimid-7-one 生成
  参考文献：
  名称：

  Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

  摘要：

  GnRH受体拮抗剂已被披露，可用于治疗男性和女性的各种与性激素相关的疾病。该发明的化合物具有以下结构：包括立体异构体、前药和其药用盐，其中Ar、B、R1、R2、R3a、R3b、R4、R5、R6和m的定义如本文所述。

  公开号：

  US06346534B1
• 作为产物：
  描述：

  位变异烟碱 在 盐酸 、 platinum(IV) oxide 作用下， 生成 dihydrometanicotine
  参考文献：
  名称：

  La Forge, Journal of the American Chemical Society, 1928, vol. 50, p. 2482

  摘要：

  DOI：

文献信息

• Nicotine chemistry
  作者：Jeffrey I. Seeman、Charles G. Chavdarian、Richard A. Kornfeld、John D. Naworal

  DOI：10.1016/s0040-4020(01)96505-6

  日期：1985.1

  Organolithium reagents (RLi; where R = ethyl, isopropyl,cyclopropyl,n-butyl, sec-butyl, t-butyl, vinyl) have been found to add regiospecifically to (—)-nicotine to provide a series of 6-substituted nicotinoids of low optical activity. The data presented for the organolithium additions coupled with an analysis of the addition oft-BuLi to(—)-nicotine and [2'-2H]nicotine have provided strong evidence

  已发现有机锂试剂（RLi；其中R =乙基，异丙基，环丙基，正丁基，仲丁基，叔丁基，乙烯基）会向（-）-烟碱区域特异性地添加，从而提供一系列的6-取代烟碱低光学活性。所提供的有关有机锂添加的数据以及对（-）-烟碱和[2'- 2 H]烟碱的t-BuLi的添加的分析，为吡咯烷环开环和涉及的重合引起的新型消旋过程提供了有力的证据。尼古丁的N'-C” 2键。
• The -butylation of nicotine: novel reaction pathways and racemization studies
  作者：Charles G. Chavdarian、Jeffrey I. Seeman

  DOI：10.1016/s0040-4039(00)87384-0

  日期：1982.1

  The reaction of nicotine with -butyllithium gives 6--butylnicotine () and two novel pyrrolidine ring cleaved products, and ; mechanisms for the racemization of , , and were elucidated by reacting -butyllithium with nicotine-2′-d1.

  与尼古丁的反应丁基锂给出6- -butylnicotine（ ）和两个新的吡咯烷环裂解产品，和; 对的外消旋化的机制，以及通过反应阐明丁基锂与尼古丁-2'- d 1。
• Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
  申请人：Cytovia, Inc.

  公开号：US20030078292A1

  公开（公告）日：2003-04-24

  The present invention is directed to gambogic acid, analogs and derivatives thereof, represented by the general Formulae I-III: 1 wherein R 1 -R 5 are defined herein. The present invention also relates to the discovery that compounds having Formula I-III are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled cell growth and spread of abnormal cells occurs.

  本发明涉及以通式I-III所表示的甘黄酸及其类似物和衍生物，其中R1-R5在此定义。本发明还涉及发现具有I-III式的化合物是caspase激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导细胞死亡，在各种临床病情中，不受控制的细胞生长和异常细胞的扩散。
• Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands
  申请人：Hendrix James A.

  公开号：US20090247509A1

  公开（公告）日：2009-10-01

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其表现出对多巴胺D3受体的选择性结合。另一方面，本发明涉及一种治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，该方法包括向需要此类治疗的患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神疾病、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔斯-德-拉-图雷综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备所述化合物的方法以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。
• Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20070161641A1

  公开（公告）日：2007-07-12

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates is to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其具有选择性地与多巴胺D3受体结合。另一方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，包括对患者进行治疗，向患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及所述化合物的制备过程，以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。